Nature Communications (May 2016)
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
- Monica Florio,
- Kannan Gunasekaran,
- Marina Stolina,
- Xiaodong Li,
- Ling Liu,
- Barbara Tipton,
- Hossein Salimi-Moosavi,
- Franklin J. Asuncion,
- Chaoyang Li,
- Banghua Sun,
- Hong Lin Tan,
- Li Zhang,
- Chun-Ya Han,
- Ryan Case,
- Amy N. Duguay,
- Mario Grisanti,
- Jennitte Stevens,
- James K. Pretorius,
- Efrain Pacheco,
- Heidi Jones,
- Qing Chen,
- Brian D. Soriano,
- Jie Wen,
- Brenda Heron,
- Frederick W. Jacobsen,
- Emil Brisan,
- William G. Richards,
- Hua Zhu Ke,
- Michael S. Ominsky
Affiliations
- Monica Florio
- Cardiometabolic Disorders, Amgen Inc.
- Kannan Gunasekaran
- Therapeutic Discovery, Amgen Inc.
- Marina Stolina
- Cardiometabolic Disorders, Amgen Inc.
- Xiaodong Li
- Cardiometabolic Disorders, Amgen Inc.
- Ling Liu
- Therapeutic Discovery, Amgen Inc.
- Barbara Tipton
- Therapeutic Discovery, Amgen Inc.
- Hossein Salimi-Moosavi
- Pharmacokinetics & Drug Metabolism, Amgen Inc.
- Franklin J. Asuncion
- Cardiometabolic Disorders, Amgen Inc.
- Chaoyang Li
- Cardiometabolic Disorders, Amgen Inc.
- Banghua Sun
- Cardiometabolic Disorders, Amgen Inc.
- Hong Lin Tan
- Cardiometabolic Disorders, Amgen Inc.
- Li Zhang
- Cardiometabolic Disorders, Amgen Inc.
- Chun-Ya Han
- Cardiometabolic Disorders, Amgen Inc.
- Ryan Case
- Therapeutic Discovery, Amgen Inc.
- Amy N. Duguay
- Therapeutic Discovery, Amgen Inc.
- Mario Grisanti
- Cardiometabolic Disorders, Amgen Inc.
- Jennitte Stevens
- Therapeutic Discovery, Amgen Inc.
- James K. Pretorius
- Comparative Biology & Safety Sciences, Amgen Inc.
- Efrain Pacheco
- Comparative Biology & Safety Sciences, Amgen Inc.
- Heidi Jones
- Therapeutic Discovery, Amgen Inc.
- Qing Chen
- Therapeutic Discovery, Amgen Inc.
- Brian D. Soriano
- Therapeutic Discovery, Amgen Inc.
- Jie Wen
- Process Development, Amgen Inc.
- Brenda Heron
- Comparative Biology & Safety Sciences, Amgen Inc.
- Frederick W. Jacobsen
- Therapeutic Discovery, Amgen Inc.
- Emil Brisan
- Therapeutic Discovery, Amgen Inc.
- William G. Richards
- Cardiometabolic Disorders, Amgen Inc.
- Hua Zhu Ke
- Cardiometabolic Disorders, Amgen Inc.
- Michael S. Ominsky
- Cardiometabolic Disorders, Amgen Inc.
- DOI
- https://doi.org/10.1038/ncomms11505
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 14
Abstract
Antibodies that block the Wnt inhibitors sclerostin and DKK- 1 enhance bone formation and fracture repair. Here the authors show these monospecific antibodies induce compensatory mechanisms that limit efficacy, and have designed a sclerostin/DKK-1 bispecific antibody that promotes superior fracture repair in rodents and bone formation in primates.
